Home / Knowledge Centre /

Overcoming the Challenges of Taking RNA Biomarkers into Clinical Trials

RNA Gene expression signatures (GESs) offer tremendous potential to classify patients into molecular subgroups of relevance for prognostic & predictive utilities. However, variations in gene expression caused by technical imprecision in the analysis process, has led to uncertainty regarding the suitability of GES for clinical trial stratification.

Download this complimentary webinar to explore key considerations in the development & analytical validation of developing RNA biomarkers suitable for clinical stratification.

Topics in this presentation include:

  • Lessons learned during the development & validation of an in-house developed Next Generation Sequencing (NGS) gene expression signature
  • Supporting evidence for Gene Expression Signature suitability for clinical trials
  • Innovative reporting of GES with a software solution
View Resource
Almac Logo

Diagnostic Services

Your global partner for biomarker discovery, development & commercialisation.

Genomic Services

We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.

Clinical Trial Assays

Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.

Companion Diagnostics

A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.

Learn More

Please complete this form to view the Webinar

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies